Compare SOPH & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOPH | PROF |
|---|---|---|
| Founded | 2011 | N/A |
| Country | Switzerland | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 374.1M | 243.2M |
| IPO Year | 2021 | 2017 |
| Metric | SOPH | PROF |
|---|---|---|
| Price | $4.99 | $6.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $7.50 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 87.4K | 61.0K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | N/A | ★ 0.19 |
| Revenue | N/A | ★ $16,098,000.00 |
| Revenue This Year | $23.09 | $92.40 |
| Revenue Next Year | $19.57 | $64.10 |
| P/E Ratio | ★ N/A | $35.95 |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $2.59 | $3.92 |
| 52 Week High | $5.70 | $8.95 |
| Indicator | SOPH | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 51.97 | 50.78 |
| Support Level | $4.54 | $5.81 |
| Resistance Level | $5.46 | $7.07 |
| Average True Range (ATR) | 0.37 | 0.38 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 43.81 | 23.67 |
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.